Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
Status:
Terminated
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
Open label, single-arm phase II study of avastin combined with fluorouracil, doxorubicin and
streptozocin administered in 28-day cycles. Treatment will continue until progression of
disease, or until withdrawal due to toxicity, or up to a maximum of 12 cycles (48 weeks). In
order to reduce the risk of cardiac toxicity, doxorubicin will be administered for a maximum
of 8 cycles. If disease has not progressed after 12 cycles of treatment, avastin monotherapy
will continue until disease progression or withdrawal due to toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute